<DOC>
	<DOC>NCT02717741</DOC>
	<brief_summary>Tafetinib is an oral multitargeted tyrosine kinase inhibitor that inhibits Vascular Endothelial Growth Factor Receptor (VEGFR). This phase I trial was conducted to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of tafetinib in Chinese patients with advance solid tumor. The study are conducting in Cancer Hospital Chinese Academy of Medical Sciences.</brief_summary>
	<brief_title>A Study of Tafetinib in Chinese Patients With Advanced Solid Tumor</brief_title>
	<detailed_description />
	<criteria>Adult patients with histologically confirmed advanced solid malignancies. ECOG score 01. 1865 years old. Withdrawal other chemotherapy drugs more than 30 days. No nitrosoureas or mitomycin C within the previous 6 weeks. Function of organs must meet the following requirements: Neutrophil count ≥1500/ul; AST and ALT≤1.5 times the upper limit of normal (ULN); Total serum bilirubin≤1.5 times ULN; Hemoglobin≥90g/L; Platelet≥100000/ul; The creatinine in the normal range or creatinine clearance rate ≥60ml/min; Left ventricular ejection fraction (LVEF) ≥50%; Females of childbearing age are required to be practicing effective contraceptive measures and to have a negative serum or urine pregnancy test before study. Written informed consent is obtained. included a history of or current brain metastases, clinically significant cardiovascular disease or uncontrolled hypertension.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>